NeoRelapse: Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (clinicaltrials.gov) - Oct 20, 2026 - P2 | N=0 | Withdrawn | Sponsor: University of Utah | N=25 ➔ 0 | Trial completion date: Aug 2030 ➔ Oct 2026 | Recruiting ➔ Withdrawn | Trial primary completion date: Aug 2027 ➔ Oct 2026
Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Melanoma • Oncology • Solid Tumor
|